|
Name |
1-Bromodocosane
|
| Molecular Formula | C22H45Br | |
| IUPAC Name* |
1-bromodocosane
|
|
| SMILES |
CCCCCCCCCCCCCCCCCCCCCCBr
|
|
| InChI |
InChI=1S/C22H45Br/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h2-22H2,1H3
|
|
| InChIKey |
QYOXLKAKUAASNA-UHFFFAOYSA-N
|
|
| Synonyms |
1-Bromodocosane; 6938-66-5; Docosane, 1-bromo-; Behenyl bromide; Docosyl bromide; n-Docosyl bromide; docosylbromide; EINECS 230-069-4; 2-Chloro-3-pyridineaceticacid; SCHEMBL318151; DTXSID3064510; NSC53991; ZINC6921162; MFCD00013543; NSC 53991; NSC-53991; AKOS015843178; DB-055266; B0392; CS-0152202; FT-0607526; A22880; F11114; EN300-6494012; 5-(p-nitrophenyl)-2-furaldehyde;5-(P-Nitrophenyl)-2-furancarbaldehyde
|
|
| CAS | 6938-66-5 | |
| PubChem CID | 81355 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 389.5 | ALogp: | 12.5 |
| HBD: | 0 | HBA: | 0 |
| Rotatable Bonds: | 20 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
| Heavy Atoms: | 23 | QED Weighted: | 0.125 |
| Caco-2 Permeability: | -5.162 | MDCK Permeability: | 0.00000549 |
| Pgp-inhibitor: | 0 | Pgp-substrate: | 0 |
| Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.284 |
| 30% Bioavailability (F30%): | 0.999 |
| Blood-Brain-Barrier Penetration (BBB): | 0.015 | Plasma Protein Binding (PPB): | 98.52% |
| Volume Distribution (VD): | 4.516 | Fu: | 1.21% |
| CYP1A2-inhibitor: | 0.076 | CYP1A2-substrate: | 0.155 |
| CYP2C19-inhibitor: | 0.19 | CYP2C19-substrate: | 0.055 |
| CYP2C9-inhibitor: | 0.046 | CYP2C9-substrate: | 0.958 |
| CYP2D6-inhibitor: | 0.154 | CYP2D6-substrate: | 0.045 |
| CYP3A4-inhibitor: | 0.167 | CYP3A4-substrate: | 0.024 |
| Clearance (CL): | 3.451 | Half-life (T1/2): | 0.022 |
| hERG Blockers: | 0.41 | Human Hepatotoxicity (H-HT): | 0.026 |
| Drug-inuced Liver Injury (DILI): | 0.699 | AMES Toxicity: | 0.056 |
| Rat Oral Acute Toxicity: | 0.064 | Maximum Recommended Daily Dose: | 0.048 |
| Skin Sensitization: | 0.968 | Carcinogencity: | 0.05 |
| Eye Corrosion: | 0.993 | Eye Irritation: | 0.941 |
| Respiratory Toxicity: | 0.691 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000442 | ![]() |
0.861 | D00AOJ | ![]() |
0.861 | ||
| ENC000449 | ![]() |
0.861 | D07ILQ | ![]() |
0.512 | ||
| ENC000923 | ![]() |
0.827 | D00STJ | ![]() |
0.496 | ||
| ENC000446 | ![]() |
0.827 | D00FGR | ![]() |
0.479 | ||
| ENC000755 | ![]() |
0.827 | D0Z5SM | ![]() |
0.458 | ||
| ENC000761 | ![]() |
0.819 | D05ATI | ![]() |
0.390 | ||
| ENC000432 | ![]() |
0.819 | D0O1PH | ![]() |
0.385 | ||
| ENC001173 | ![]() |
0.805 | D0T9TJ | ![]() |
0.320 | ||
| ENC000359 | ![]() |
0.795 | D0P1RL | ![]() |
0.302 | ||
| ENC000433 | ![]() |
0.795 | D0Z1QC | ![]() |
0.295 | ||